350 related articles for article (PubMed ID: 20679606)
1. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
O'Connell MJ; Lavery I; Yothers G; Paik S; Clark-Langone KM; Lopatin M; Watson D; Baehner FL; Shak S; Baker J; Cowens JW; Wolmark N
J Clin Oncol; 2010 Sep; 28(25):3937-44. PubMed ID: 20679606
[TBL] [Abstract][Full Text] [Related]
2. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N
J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557
[TBL] [Abstract][Full Text] [Related]
3. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
Wolmark N; Colangelo L; Wieand S
Semin Oncol; 2001 Feb; 28(1 Suppl 1):9-13. PubMed ID: 11273592
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Wilkinson NW; Yothers G; Lopa S; Costantino JP; Petrelli NJ; Wolmark N
Ann Surg Oncol; 2010 Apr; 17(4):959-66. PubMed ID: 20082144
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
Wolmark N; Rockette H; Mamounas E; Jones J; Wieand S; Wickerham DL; Bear HD; Atkins JN; Dimitrov NV; Glass AG; Fisher ER; Fisher B
J Clin Oncol; 1999 Nov; 17(11):3553-9. PubMed ID: 10550154
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.
Wolmark N; Bryant J; Smith R; Grem J; Allegra C; Hyams D; Atkins J; Dimitrov N; Oishi R; Prager D; Fehrenbacher L; Romond E; Colangelo L; Fisher B
J Natl Cancer Inst; 1998 Dec; 90(23):1810-6. PubMed ID: 9839521
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.
Sobrero A; Frassineti G; Falcone A; Dogliotti L; Rosso R; Di Costanzo F; Bruzzi P;
Br J Cancer; 2005 Jan; 92(1):24-9. PubMed ID: 15611795
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04).
Mamounas E; Wieand S; Wolmark N; Bear HD; Atkins JN; Song K; Jones J; Rockette H
J Clin Oncol; 1999 May; 17(5):1349-55. PubMed ID: 10334518
[TBL] [Abstract][Full Text] [Related]
10. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.
Arkenau HT; Bermann A; Rettig K; Strohmeyer G; Porschen R;
Ann Oncol; 2003 Mar; 14(3):395-9. PubMed ID: 12598344
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
Kelsen DP; Saltz L; Cohen AM; Yao TJ; Enker W; Tong W; Tao Y; Bertino JR
Cancer; 1994 Oct; 74(8):2224-33. PubMed ID: 7922973
[TBL] [Abstract][Full Text] [Related]
13. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy for colon cancer.
Macdonald JS
CA Cancer J Clin; 1997; 47(4):243-56. PubMed ID: 9242173
[TBL] [Abstract][Full Text] [Related]
15. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
Porschen R; Bermann A; Löffler T; Haack G; Rettig K; Anger Y; Strohmeyer G;
J Clin Oncol; 2001 Mar; 19(6):1787-94. PubMed ID: 11251010
[TBL] [Abstract][Full Text] [Related]
17. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Zisiadis A; Dafni U; Konstantaras C; Hatzitheoharis G; Papavramidis S; Bousoulegas A; Basdanis G; Giannoulis E; Dokmetzioglou J; Katsohis C; Nenopoulou E; Karvounis N; Briassoulis E; Aravantinos G; Kosmidis P; Skarlos D; Pavlidis N
Oncology; 2000 Apr; 58(3):227-36. PubMed ID: 10765125
[TBL] [Abstract][Full Text] [Related]
18. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
Scheithauer W; Kornek GV; Marczell A; Karner J; Salem G; Greiner R; Burger D; Stöger F; Ritschel J; Kovats E; Vischer HM; Schneeweiss B; Depisch D
Br J Cancer; 1998 Apr; 77(8):1349-54. PubMed ID: 9579845
[TBL] [Abstract][Full Text] [Related]
19. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
Wolmark N; Rockette H; Fisher B; Wickerham DL; Redmond C; Fisher ER; Jones J; Mamounas EP; Ore L; Petrelli NJ
J Clin Oncol; 1993 Oct; 11(10):1879-87. PubMed ID: 8410113
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
